CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,282 enrolled
Drug / intervention
Eluxadoline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01553591
NCT01553591Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Pharmaceuticals, Inc·interventional·Posted Mar 14, 2012·Updated Sep 4, 2018

In Brief

A Phase 3 clinical trial evaluating Eluxadoline and Placebo for Irritable Bowel Syndrome. Completed, enrolled 1,282 participants across 283 sites in 3 countries.

Detailed Summary

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesCanada, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 14, 2012
Enrollment StartMay 29, 2012
Primary CompletionJul 29, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.3 years ago

Interventions

Eluxadolinedrug

Oral tablets twice daily

Placebodrug

Oral tablets twice daily